The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Long-term survival with oral azacitidine: An update from the QUAZAR AML-001 trial
The QUAZAR AML-001 trial has been extensively covered on our hub, with key results demonstrating that maintenance with oral azacitidine (AZA) improves overall survival (OS) and relapse-free survival (RFS) when compared with placebo in elderly patients with acute myeloid leukemia (AML) in first complete remission. At the European Hematology Association (EHA) 2022 Congress, Andrew Wei presented updated results for long-term survival with oral azacitidine from this trial,1 which we are pleased to summarize here.
Methods
- Long-term survival was defined as surviving ≥3 years from randomization, with these patients grouped into a “long-term survival (LTS)” cohort
- In the non-LTS cohort, patients either died within 3 years from randomization, withdrew consent, or were lost during follow-up
Results
- Overall, 29.7% (140/472) of patients were included in the LTS cohort, including 34.9% (83/238) of patients receiving oral azacitidine, and 24.4% (57/234) of patients receiving placebo
- A total of 6.3% (15/238) of patients receiving oral azacitidine received allogeneic hematopoietic stem cell transplant (allo-HSCT)
- Seven of these patients were in the non-LTS cohort, and eight were in the LTS cohort
- In the placebo arm, 13.7% (n = 32) of patients received allo-HSCT after treatment discontinuation, and 16 of whom were in the LTS cohort
Multivariable analysis
- In a multivariable analysis controlling for all other covariates, oral azacitidine was significantly associated with improved LTS compared to placebo (p = 0.010)
- Other variables significantly associated with LTS were measurable residual disease (MRD) negativity at baseline (p = 0.002), presence of the NPM1 mutation at diagnosis (p < 0.001), and intermediate versus poor cytogenetic risk at diagnosis (p = 0.007)
In summary, updated results from the QUAZAR AML-001 trial demonstrated that treatment with oral azacitidine led to improved LTS outcomes compared with placebo (34.9% vs 24.4%). Oral azacitidine was also significantly associated with improved LTS in a multivariable analysis.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content